company background image
6744

Feng Chi Biotech TPEX:6744 Stock Report

Last Price

NT$18.35

Market Cap

NT$282.6m

7D

-1.9%

1Y

-27.2%

Updated

28 Sep, 2022

Data

Company Financials
6744 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends1/6

6744 Stock Overview

Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services.

Feng Chi Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Feng Chi Biotech
Historical stock prices
Current Share PriceNT$18.35
52 Week HighNT$26.50
52 Week LowNT$18.20
Beta-0.020
1 Month Change-4.43%
3 Month Change-21.92%
1 Year Change-27.18%
3 Year Change-42.66%
5 Year Changen/a
Change since IPO-61.93%

Recent News & Updates

Shareholder Returns

6744TW HealthcareTW Market
7D-1.9%-3.0%-5.1%
1Y-27.2%8.5%-19.0%

Return vs Industry: 6744 underperformed the TW Healthcare industry which returned 8.5% over the past year.

Return vs Market: 6744 underperformed the TW Market which returned -19% over the past year.

Price Volatility

Is 6744's price volatile compared to industry and market?
6744 volatility
6744 Average Weekly Movement5.0%
Healthcare Industry Average Movement4.6%
Market Average Movement5.1%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 6744 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6744's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a28n/ahttps://www.fcbiotech.com.tw

Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. The company is based in Taipei, Taiwan.

Feng Chi Biotech Fundamentals Summary

How do Feng Chi Biotech's earnings and revenue compare to its market cap?
6744 fundamental statistics
Market CapNT$282.59m
Earnings (TTM)NT$21.29m
Revenue (TTM)NT$187.05m

13.3x

P/E Ratio

1.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6744 income statement (TTM)
RevenueNT$187.05m
Cost of RevenueNT$106.21m
Gross ProfitNT$80.85m
Other ExpensesNT$59.55m
EarningsNT$21.29m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.38
Gross Margin43.22%
Net Profit Margin11.38%
Debt/Equity Ratio0%

How did 6744 perform over the long term?

See historical performance and comparison

Dividends

6.8%

Current Dividend Yield

90%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 6744 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6744?

Other financial metrics that can be useful for relative valuation.

6744 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 6744's PE Ratio compare to its peers?

6744 PE Ratio vs Peers
The above table shows the PE ratio for 6744 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.4x
6615 Sofiva GenomicsLtd
18.7x17.8%NT$906.8m
6518 Concord Medical
19.5xn/aNT$956.7m
6637 Medical Imaging
11.1xn/aNT$911.6m
1784 BIONET
124.6xn/aNT$1.8b
6744 Feng Chi Biotech
13.3xn/aNT$282.6m

Price-To-Earnings vs Peers: 6744 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (45.4x).


Price to Earnings Ratio vs Industry

How does 6744's PE Ratio compare vs other companies in the Asian Healthcare Industry?

Price-To-Earnings vs Industry: 6744 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the Asian Healthcare industry average (17.4x)


Price to Earnings Ratio vs Fair Ratio

What is 6744's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6744 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6744's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6744 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6744 (NT$18.35) is trading above our estimate of fair value (NT$17.01)

Significantly Below Fair Value: 6744 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Feng Chi Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.1%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Feng Chi Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Feng Chi Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Feng Chi Biotech performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6744 has high quality earnings.

Growing Profit Margin: 6744's current net profit margins (11.4%) are lower than last year (14.6%).


Past Earnings Growth Analysis

Earnings Trend: 6744's earnings have grown by 12.5% per year over the past 5 years.

Accelerating Growth: 6744's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6744 had negative earnings growth (-18.5%) over the past year, making it difficult to compare to the Healthcare industry average (14.6%).


Return on Equity

High ROE: 6744's Return on Equity (9.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Feng Chi Biotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 6744's short term assets (NT$278.3M) exceed its short term liabilities (NT$70.7M).

Long Term Liabilities: 6744 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 6744 is debt free.

Reducing Debt: 6744 has not had any debt for past 5 years.

Debt Coverage: 6744 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6744 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Feng Chi Biotech current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


6.81%

Current Dividend Yield

Dividend Yield vs Market

Feng Chi Biotech Dividend Yield vs Market
How does Feng Chi Biotech dividend yield compare to the market?
SegmentDividend Yield
Company (Feng Chi Biotech)6.8%
Market Bottom 25% (TW)2.5%
Market Top 25% (TW)6.9%
Industry Average (Healthcare)3.0%
Analyst forecast in 3 Years (Feng Chi Biotech)n/a

Notable Dividend: 6744's dividend (6.81%) is higher than the bottom 25% of dividend payers in the TW market (2.51%).

High Dividend: 6744's dividend (6.81%) is low compared to the top 25% of dividend payers in the TW market (6.91%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 6744 has been paying a dividend for less than 10 years.

Growing Dividend: 6744's dividend payments have increased, but the company has only paid a dividend for 2 years.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (90.4%), 6744's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (92.9%), 6744's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Feng Chi Biotech has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 6744?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Feng Chi Biotech Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Feng Chi Biotech Corp.
  • Ticker: 6744
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: NT$282.590m
  • Shares outstanding: 15.40m
  • Website: https://www.fcbiotech.com.tw

Number of Employees


Location

  • Feng Chi Biotech Corp.
  • 1, No.5, Shaoxing North Street
  • 5th Floor
  • Taipei
  • 100
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6744TPEX (Taipei Exchange)YesRegistered Common SharesTWTWDSep 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.